Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.41 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4701075 | 0.83 | CYP2D6 (0.43) | — | |
| SCHEMBL1509544 | 0.80 | KCNH2 (0.46) | SIGMAR1 | |
| SCHEMBL1877934 | 0.75 | HRH3 (0.68) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL5651768 | 0.75 | SIGMAR1 (0.64) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL2762024 | 0.73 | HRH3 (0.71) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL2761916 | 0.73 | HRH3 (0.71) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL12992754 | 0.72 | CYP2D6 (0.65) | ALDH1A1 | |
| Hydrochloric Acid SCHEMBL916318 | 0.72 | HRH3 (0.69) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 | |
| SCHEMBL1509554 | 0.72 | LMNA (0.70) | SIGMAR1HRH3LMNAALDH1A1MBTD1 | |
| Hydrochloric Acid SCHEMBL9034274 | 0.72 | HRH3 (0.69) | SIGMAR1HRH3ALDH1A1MBTD1L3MBTL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| EP-1960382-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | ChemBridge Research Laboratories, Inc. (US) | 2008-08-27 | — | — | EP | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | SIGMAR1 4395/4885HRH3 868/4885LMNA 4192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.